- BRACAnalysis CDx is also a complementary diagnostic for maintenance therapy in patients with ovarian cancer who have a germline BRCA1 or BRCA2 mutation.
BRACAnalysis CDx Indications for ovarian cancer
- Treatment with Lynparza for patients with metastatic breast cancer
- 4th line treatment with Lynparza for patients with ovarian cancer
2nd line maintenance therapy in ovarian cancer with Zejula
Mechanism of Action: BRCA and PARP
endogenous DNA damage
polyADP ribose polymerase (PARP) and BRCA both function to repair DNA
Tumors with BRCA mutations already have a DNA repair defect
Inhibiting PARP in BRCA deficient cells prevents the cell from replicating- effectively killing the cancer cells
BRACAnalysis CDx is intended to detect germline BRCA1 and BRCA2 variants and provide a clinical interpretation of the identified variants.
All components are incorporated in Myriad’s FDA-approved device.
PARPi Indications for Use
|Lynparza||Metastatic Breast Cancer||Treatment for patients at any age
|Robson et al. N Engl J Med (2017). 10.1056/NEJMoa1706450|
|Lynparza||Ovarian Cancer||4th line+ treatment
|2nd line+ maintenance therapy
|Kaufman et al.|
|Zejula||Ovarian Cancer||2nd line+ maintenance therapy
March 2017 therapy
|Mirza et al. N Engl J Med. (2016). 375:2154-2164.|